The macro-economic effects of health co-benefits associated with climate change

mitigation strategies by Smith, RD et al.
Smith, RD; Keogh-Brown, MR; Jensen, HT; Chalabi, Z; Dangour,
AD; Davies, M; Edwards, P; Garnett, T; Givoni, M; Griffiths, UK;
Hamilton, I; Jarrett, J; Roberts, I; Wilkinson, P; Woodcock, J; Haines,
A (2013) The macro-economic effects of health co-benefits associated
with climate change mitigation strategies. (Unpublished)
Downloaded from: http://researchonline.lshtm.ac.uk/1217046/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the author
Working Paper Under Revision 
 
1 
 
The macro-economic effects of health co-benefits associated with climate change 
mitigation strategies 
 
Authors 
Richard D Smith*  
Marcus Keogh-Brown 
Henning Tarp Jensen 
Zaid Chalabi 
Alan D Dangour 
Mike Davies 
Phil Edwards 
Tara Garnett 
Moshe Givoni 
Ulla K. Griffiths 
Ian Hamilton 
James Jarrett 
Ian Roberts 
Paul Wilkinson 
James Woodcock 
Andy Haines 
Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK. 
Prof R Smith PhD, M. Keogh-Brown PhD, Z. Chalabi PhD, U. K. Griffiths PhD, Prof P. 
Wilkinson FRCP, Prof A. Haines F Med Sci 
Working Paper Under Revision 
 
2 
 
Faculty of Epidemiology and Population, Health London School of Hygiene and Tropical 
Medicine, UK. A. Dangour PhD, P. Edwards PhD, Prof I Roberts PhD, Prof A. Haines F 
Med Sci 
Bartlett School of Graduate Studies, University College London UK. Prof M. Davies PhD, 
I. Hamilton MSc  
Food and Climate Research Network, University of Surrey, Guildford, UK. T. Garnett MA 
Norwich Medical School, Health Economics Group, University of East Anglia, UK. J. Jarrett 
PhD 
Institute of Food and Resource Economics, University of Copenhagen, Denmark. H. T. 
Jensen PhD 
Transport Studies Unit, School of Geography and the Environment University of Oxford UK 
and Department of Geography and Human Environment, Tel-Aviv University, Israel 
M.Givoni PhD  
UKCRC Centre for Diet and Activity Research (CEDAR), Institute of Public Health, 
University of Cambridge UK J. Woodcock PhD 
 
*Corresponding author: Professor Richard Smith, Faculty of Public Health and Policy, 
London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, WC1H 
9SH. Email: Richard.Smith@lshtm.ac.uk 
 
  
Working Paper Under Revision 
 
3 
 
Summary 
The UK government has specific targets for greenhouse gas (GHG) emission reduction to 
lower the risk of dangerous climate change. Strategies to reduce GHG emissions are 
sometimes perceived as expensive and difficult to implement but previous work has 
demonstrated significant potential health co-benefits from ‘Active Travel and low carbon 
driving’, ‘Housing Insulation/Ventilation’, and ‘Healthy Diet’ scenarios which may be 
attractive to policymakers. Here a Computable General Equilibrium model is used to assess 
the financial effects of such health co-benefits on the wider economy including changes in 
labour force, social security payments and healthcare costs averted. Results suggest that for 
all scenarios the financial impacts of the health co-benefits will be positive and increased 
active travel in particular is likely to make a substantial contribution, largely due to health 
care costs averted. 
 
Strategies to reduce GHG emissions and improve health are likely to result in substantial and 
increasing positive contributions to the economy which may offset some potential economic 
costs and thereby be seen more favourably in times of economic austerity.  
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Introduction 
Evidence suggests that, in the absence of policies to greatly reduce greenhouse gas (GHG) 
emissions, major climate change could take place during this century. At global mean 
temperature increases of above 2°C more than pre-industrial levels the likelihood of a range 
of serious impacts is high1. It seems likely that the 2°C threshold will be exceeded, in view of 
current rates of emission increases2, with one estimate3 suggesting a 5% probability that the 
upper limit of warming from a doubling of carbon dioxide could exceed 7·1°C. At this point 
parts of the world may become effectively uninhabitable4. 
 
It is clear that deep cuts in GHG emissions are needed to avert ‘dangerous’ climate change, 
and the Committee on Climate Change in the UK concluded that for the UK an 80% cut in 
emissions by 2050, relative to 1990 levels, is an appropriate, although probably conservative, 
contribution to a 50% cut in global emissions5. More recently, the committee suggested a 
46% cut over the next 20 years and a further 62% cut between 2030 and 2050 to reach the 
2050 target6. 
 
Strategies to reduce GHG emissions are sometimes perceived as expensive and difficult to 
implement but there are a number of collateral benefits (co-benefits) which can offset 
increases in costs and make them more attractive to policymakers. These include health co-
benefits. For example, improving insulation and ventilation of existing housing stock can 
reduce exposure to cold and to a number of indoor pollutants whilst reducing GHG 
emissions; reducing the use of private cars and increasing active travel through more walking 
and cycling can reduce the adverse health effects of a sedentary lifestyle; and decreasing 
consumption of animal products in high consuming economies can reduce saturated fat intake 
as well as reducing GHG emissions from ruminants7-9. 
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The Lancet published a series of papers, just prior to  the UN Climate Change Conference in 
Copenhagen in December 2009, which indicated the likely health co-benefits associated with 
GHG reduction which might be achieved through three strategies in the UK: ‘Active Travel 
and low carbon driving’, ‘Housing Insulation/Ventilation’, and ‘Healthy Diet (from reduced 
animal product consumption)’10-15. This paper builds on that work, to assess the financial 
impacts of such health co-benefits on the wider economy, following an innovative approach 
previously applied with respect to agriculture and nutrition16. Especially within a context of 
economic austerity in many countries, strategies to reduce GHG emissions will be seen more 
favourably if the health benefits they yield are not just substantial in themselves but also 
make positive contributions to the economy to offset any potential economic costs of 
implementing such strategies. 
 
 
 
 
 
 
 
 
 
 
  
Research in context panel 
Interpretation 
A number of new mitigation initiatives are necessary to achieve the planned 50% 
greenhouse gas (GHG) emission reduction targets for the UK by 2030. Our study 
assesses the macroeconomic effect of health co-benefits  associated with interventions 
designed to meet sector-specific reduction targets in UK GHG emissions by 2030. 
Health co-benefits were based on increased active travel (walking and cycling) in 
urban areas, improved diets (reduced dietary cholesterol and saturated fat intake 
associated with reduced consumption of animal products ), and improved housing 
insulation and ventilation control. The changes in disease burden were used to derive 
health effects on the UK labour force, healthcare costs, and social security transfers, 
and a Computable General Equilibrium model was employed to indicate the 
macroeconomic effects of these health co-benefits. Macroeconomic effects as a result 
of the improvements in health are positive and increase over time for all scenarios.  
These could offset some of the costs of implementing policies to reduce GHG 
emissions and make them more attractive to policymakers. 
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Methods 
GHG reduction strategies assessed 
The strategies previously reported in The Lancet were designed to be of the type and scale 
needed to meet locally-specific UK GHG mitigation targets for 2030 and used a number of 
different assumptions depending on the sector concerned.10,11,13 The reductions in GHG 
emissions modelled were consistent with the recommendations of the UK’s Climate Change 
Committee. In this current paper, three scenarios corresponding to the three strategies 
previously reported were selected in order to isolate the macroeconomic impact of the health 
co-benefits that might be achieved from these strategies. The scenarios are: 
 
(i) ‘Active Travel and low carbon driving’ (transport sector) scenario: the health co-benefits 
of an assumed immediate (2011) 2·5 fold increase in walking and 8 fold increase in cycling 
in urban England and Wales; 
(ii) ‘Healthy Diet’ (food and agriculture sector) scenario: the health co-benefits of an 
assumed immediate (2011) UK-wide 30% reduction in dietary saturated fat consumption; 
(iii) ‘Housing Insulation/Ventilation’ (household energy sector) scenario: the health co-
benefits of an assumed gradual (2011-30) improvement in home insulation/ventilation UK-
wide to improve indoor temperature to an ‘optimal’ average of 18°C together with  changes 
in the level of indoor pollutants phased over 20 years. 
 
The different assumptions about the rate of implementation were made because changes in 
active travel and animal product consumption could in theory be made be made quite rapidly, 
whereas housing modifications would inevitably have to be implemented over substantial 
time periods. 
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These scenarios and the assumptions underpinning them are detailed in Appendix A. The 
economic impacts of the three scenarios were measured using a Computable General 
Equilibrium (CGE) model. The modelled health co-benefits included changes in labour force, 
social security payments (reduced benefits for working age people and increased pensions for 
old age people), and healthcare savings. The objective of this exercise was to highlight the 
economic contribution of the health co-benefits of GHG emission strategies and not to model 
GHG emission abatement policies as a whole. Specifically, abatement cost aspects of the 
strategies (including increased investment costs for lower carbon driving and household 
insulation/ventilation, and policies to reduce animal product production and consumption) 
were omitted from scenarios in order to isolate the health effects and their economic 
consequences. 
 
Health impact analysis 
The approach used to determine the health impacts resulting from these three scenarios is the 
WHO comparative risk assessment (CRA) approach.17 The health impacts reported in the 
previous Lancet series10,11,13 were translated in this paper into a sequence of labour force, 
social security and healthcare cost ‘shocks’ and imposed on the UK CGE model. The 
economic shocks were derived from measures of disease/injury incidence, Years of Life Lost 
(YLL, mortality), and Years of healthy Life lost due to Disability (YLD, morbidity), and 
were assumed to occur immediately or with a time-lag (1-20 years, depending on the health 
outcome) between the scenario-related changes in exposure and the associated observable 
health effects (Table 1). 
 
The calculated YLL and YLD health effects do not have an explicit time dimension. 
Dynamic health effect profiles (2011-30) therefore had to be developed. (Details of the 
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assumptions used are outlined in detail in Appendix B and the specific parameters of the  lag 
period for each health effect are included in Appendix C). Briefly, an increase in road traffic 
injuries was assumed to occur immediately upon exposure to increased active travel. With 
immediate scenario implementation (transport), a constant steady-state change in injuries was 
assumed to occur immediately and continue throughout 2011-30. With gradual scenario 
implementation (household energy), a constant population-wide steady-state reduction in 
indoor cold was only reached at the end of the time horizon in 2030. The reduction in 
prevalence of common mental disorder (CMD) attributable to alleviation of winter indoor 
cold was assumed to apply immediately in winter months (conservatively, this impact was 
assumed to apply for only the first season following exposure). For all other health effects 
cause-specific sigmoidal lag curves were assumed, which allowed for an ‘incubation period’ 
of no/small impact (the duration of which varied from one exposure-cause-of-illness 
combination to another) followed by a gradual increase to a steady-state level impact after a 
‘transition period’ of some years. The 1996 Global Health Statistics publication18 was used to 
distribute the health benefits by age and sex, and adjustments to the calculated YLD and YLL 
values were made to account for effects that occur beyond our 20 year horizon and to capture 
future changes in disease burdens. Age specific statistics, together with labour force 
participation rates, were also used to determine the impact of morbidity and mortality on the 
labour force (15-64) and dependents (0-14 and 65+). The demographic effects were 
subsequently used to estimate the change in social security payments that will occur through 
improvements in health (including reduced benefit payments to healthy working age people 
and increased pension payments to old age people accounting for changes in life expectancy). 
 
Finally, the potential cost savings to the health service were measured on the basis of 
estimates of reduced illness incidence. Data for the active travel scenario were imported from 
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an earlier paper19 in which the methods are described in more detail. All health cost estimates 
assumed a nominal discount rate of 3.5%, and an inflation rate of 2.9% p.a. which yields net 
present value calculations based on an implicit 0.6% real interest rate. The estimates of 
healthcare savings in this article differ from the earlier article19 for the following reason: This 
article discounts future healthcare savings by a 3.5% p.a. nominal interest rate, while the 
earlier article deflates future savings by a 2.9% inflation rate. Here, undiscounted healthcare 
savings are used as inputs to the CGE model, while net present value results are presented as 
outputs from the CGE model. Assumptions used in estimating the healthcare costs averted 
and labour force gains are outlined in the appendices. 
 
Computable General Equilibrium (CGE) model 
The model used is described in detail in Appendix D. Briefly, an economy-wide dynamically-
recursive CGE model was used to model the economic impact of the health benefits 
associated with the GHG reduction strategies outlined above. 
 
Scenario-specific dynamic profiles for health-related changes in labour supplies, healthcare 
costs, and social security transfers were, in each case, imposed on the dynamic CGE model to 
reflect future changes in disease burden associated with each scenario. The model produces a 
variety of outputs, principally focused on changes in GDP. The distribution of impacts across 
the various sectors of the economy is also provided, to indicate where major losses or gains 
may be likely to occur. This paper presents the results for the indirect macroeconomic 
impacts attributable to the health co-benefits only. 
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Results 
The health effects and health-related macroeconomic impacts for the three scenarios are 
presented in Tables 1 and 2.  
Tables 1 and 2 about here 
The results suggest that health effects, which are positive for most forms of scenario-related 
changes in exposure, also have positive net effects on the economy. Table 2 indicates that 
health co-benefits generated net economic gains of around £24·0bn overall, with active travel 
contributing £18·9bn, reduced meat and dairy consumption £4·7bn and housing insulation 
and ventilation £448m by 2030 (although with larger net gains projected after this date due to 
accrued health benefits). 
 
Taken together, the three scenarios were estimated to result in a health-related expansion of 
the labour-force of around 7,700 workers per year (154,000 accumulated worker years over 
the 20 year horizon) together with an accumulated increase in dependents of around 19,150 
per year (where dependents are defined as those members of the population who are not of 
working age). Nonetheless, the majority of economic benefits came from costs averted to the 
healthcare system, as indicated in Table 1. The reductions in healthcare costs can either be 
taken as reductions in government expenditure on the health service (standard way of 
calculating the opportunity cost of public expenditures, and the approach taken here) or more 
likely by redirecting the healthcare costs averted to other priorities within the NHS budget. 
Either way, the healthcare savings result in welfare gains for the UK population. However, 
since the mortality reductions are weighted towards those of pensionable age rather than 
working age (increasing the number of dependents), the population increase in non-workers 
is proportionally larger than the GDP gains for some scenarios and so yields negative GDP 
per capita effects in these cases.  
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Scenario specific macroeconomic effects are tabulated in Table 2 and illness specific 
contributions to the economic benefits are presented in Appendix B (Table B2). Reductions 
in disease burdens from Diabetes, Ischaemic Heart Disease (IHD), Depression, and 
Cerebrovascular disease make the largest contributions to healthcare savings, while reduced 
disease burdens from IHD, Cerebrovascular disease and depression and Diabetes make the 
largest contributions to the labour force. In the case of social security costs, IHD and 
Cerebrovascular disease make substantial contributions. 
 
Figure 1 shows that for each scenario the health-related impacts on the economy (due to 
increased labour force participation, healthcare costs averted, and increased social security 
costs) were positive throughout the period of modelling. The substantial and growing positive 
health-related impacts on GDP for the active travel and healthy diet scenarios are mainly 
attributable to healthcare costs averted which are large and cumulative over time. The gradual 
implementation of the housing insulation/ventilation scenario, which contrasts with the 
assumed immediate implementation of the active travel and healthy diet scenarios, coupled 
with the time lag for health effects (which, for this sector, do not reach their maximum until 
after the 2011-2030 modelling period), means that its health-related effects on the economy 
are considerably delayed. For all scenarios, different lag periods for individual health 
outcomes lead to differences in YLDs averted and, through changes in labour force 
participation and social security costs, to differences in macroeconomic health effects. 
 
Figure 1 about here 
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Note that the economic impact attributable to health effects from the housing 
insulation/ventilation intervention are thus not directly comparable with the scenarios for the 
other sectors because the underlying assumptions differ, especially in relation to the time 
course of implementation. Note also that cold-related mortality and morbidity were only 
partially accounted for here because the evidence base for such quantifications was 
considered limited. Furthermore, there is only very limited evidence on the mental health 
impact of the alleviation of indoor cold, and the estimate included here was therefore based 
on a conservative assumption that mental well-being would be improved only in the first year 
after the intervention. 
 
In addition, three sensitivity analyses were undertaken (as outlined in detail in Appendix E). 
These analyses test the sensitivity of results to variations in assumptions concerning: (i) the 
substitutability of labour for other factors of production; (ii) the effectiveness of the 
intervention; and (iii) changes in the discount rate. The analyses show that the degree to 
which the economy is able to absorb the additional labour supply resulting from health co-
benefits could influence the overall economic gains by a factor between -4% to +8%. In 
addition, if only half the anticipated level of active transportation were achieved, the 
reduction in economic impact would be roughly proportional. Finally, a lower discount rate 
(3%) may increase macroeconomic benefits by 7%, while a higher discount rate (4%-5%) 
may lower the cumulative GDP impact by 7%-18%. Overall, the core results may be 
considered relatively robust to changes in these three factors. 
 
Discussion 
This paper further emphasises the importance of considering the public health impacts of 
reducing GHG emissions. The previous Lancet series10-15 highlighted the health co-benefits 
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that may arise from policies to reduce GHG emissions. This paper demonstrates that these 
health co-benefits can result in significant macro-economic gains, which may be important 
when considering the costs and benefits of mitigation strategies. 
 
Clearly, the analysis undertaken here was designed to be illustrative rather than definitive, 
and there are a number of critical caveats. First, the results relate only to the effects on the 
economy of the immediate or near-term health impacts of mitigation. Abatement costs and 
other benefits of the mitigation measures were therefore not part of the analysis. Second, the 
scenarios assessed were different in their specifications; particularly with assumptions of 
immediate changes for the active travel and healthy diet scenarios, but a much slower, phased 
implementation for the housing insulation/ventilation scenario. This was done because in 
theory changes in active travel and animal product consumption could be made quite rapidly, 
whereas housing modifications would inevitably have to be implemented over substantial 
time periods. The rapidity with which health and economic benefits accrue depends on the 
speed of implementation of strategies and assumptions about the lag periods between 
interventions and changes in health. In a previous paper19 sensitivity analyses were 
undertaken to illustrate the effects of varying lag periods. 
 
Other scenario specifications can be expected to yield results which differ in their detail, 
perhaps showing substantially greater or lesser health and/or economic impacts. Future 
research would be well served by conducting a wide scope of analysis across a number of 
alternative scenarios to find points at which the balance of their GHG emission reductions, 
health and economic impacts may be optimized. In addition more evidence is needed about 
how to achieve large changes in cycling and walking, and a significant reduction in motor 
vehicle kilometres driven, in the UK. It is likely that, in order to achieve the increased active 
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travel, a large cultural shift would also be needed. However, there is considerable variation in 
how much people walk and cycle in different cities and countries and a number of cities have 
achieved large increases in cycling from a range of starting points. These include those 
starting from a low level (Barcelona, London, Paris, New York), a middling level (Berlin) 
and from a high level (Copenhagen). 
 
There are, as we have demonstrated previously13, likely to be wider variations in the health 
and economic impacts of policies between different countries with different economic 
structures; most significantly between countries at different stages of economic development. 
It is highly likely that there will be different profiles of desirability between policies 
according to the country of analysis. There is the further complication of the interdependency 
between countries through global trade that needs greater exploration; important especially as 
reducing GHG emissions to prevent dangerous climate change is a global issue and requires a 
global solution. 
 
Although there may be an element of double counting, for example of IHD co-benefits from 
both ‘healthy diet’ and ‘active travel’ scenarios, it is quite likely that the health benefits were 
underestimated. Thus, for instance, the health effects for housing insulation/ventilation are 
likely to be much higher than those indicated in the tabulated results because the peak impact 
on health would occur well after 2030 when full implementation has been achieved. Hence, 
due to gradual phasing-in, further (lagged) health co-benefits from that intervention would 
continue beyond the period we have modelled. We have also not included the health-related 
economic benefits arising from reduced urban local air pollution in the active travel scenario. 
Furthermore, the active travel scenario was limited to England and Wales. Increased active 
travel in urban parts of Scotland and Northern Ireland would result in additional health and 
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economic benefits but these have not been estimated as it was felt that the lower density of 
urban areas and climatic differences in Scotland and Northern Ireland would require a 
different parameterisation. Similarly, there were fewer diseases modelled for the healthy diet 
scenario than would likely be affected, together with no impact from substitution to, for 
example, increased fruit and vegetable consumption. If pensionable age increases in the 
future, then the projected increases in pension costs would also be reduced. Also if reductions 
in healthcare costs were reinvested in the NHS to provide additional care this would clearly 
reduce the direct benefits to the economy but would provide additional indirect benefits as a 
result of further improvements in health or investment in medical innovation.  
 
Nonetheless, the primary purpose, and the unique contribution, of the modelling undertaken 
here was to highlight the importance of looking at the economic contribution of the health co-
benefits of GHG emission strategies across a number of sectors. This is important as it 
enables assessment of: (i) sectors and population groups likely to ‘win’ and/or ‘lose’ from 
specific strategies; and (ii) types of GHG mitigation measures likely to be most beneficial in 
health and economic terms. This evidence may then be used to: (i) support the case for 
acceleration of mitigation policies; (ii) aid the improved design and implementation of such 
policies to maximise positive and minimize adverse economic or health consequences of 
GHG reductions; (iii) address urgent national and international public health priorities 
through measures targeted outside the health sector, specifically in urban transport, household 
energy and food and agriculture sectors; and (iv) further demonstrate the value of taking 
integrated, multi-sectoral, approaches to the evaluation of significant and complex social 
interventions. It is important to note though that in the absence of an overall policy 
framework to promote abatement of GHG emissions across the world economy, reductions of 
emissions in one sector would likely be counterbalanced by increases in other sectors.  
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The analyses presented here are relatively simplistic and subject to a number of uncertainties. 
These include, for example, whether healthcare savings are spent on medical research and 
treatment or invested in physical/human capital accumulation or other research and 
development, whether the labour force increases are diluted by reduced immigration, and 
whether improved health outcomes leads to increased labour productivity when at work. 
Nevertheless, highlighting both the health and economic effects together illustrates the need 
to consider the systems interaction between different policy sectors, and at different levels of 
impact (i.e. individual, regional, national, international) in developing upstream policies to 
tackle GHG emissions. 
 
Conclusion  
It is clear that considering the health co-benefits of greenhouse gas mitigation strategies can 
substantially influence the macroeconomic effects of GHG mitigation strategies and the 
threshold at which a specific policy may become cost effective. While the calculation of 
dynamic health profiles, represents an approximation, the (sometimes) long lag periods, 
which implies that health effects (oftentimes) occur outside our 20 year time horizon, means 
that our results are likely to be conservative estimates of the total macroeconomic effects and 
should be considered as illustrative of what could be achieved. Future research should seek to 
address these limitations by improved epidemiological modelling based on explicit dynamic 
life tables and by integrating the calculation of health effects within the CGE framework to 
improve the accuracy of estimates and capture the interaction between health and the 
economy. Our sensitivity analyses also showed that, whilst the absolute magnitude of the 
health co-benefits of this study may vary with the ability of labour to substitute for other 
production factors, the effectiveness of the underlying intervention and the choice of discount 
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rate, these impacts remain strong enough to warrant close attention by policymakers when 
considering the best approach to achieving the deep cuts in emissions that will be necessary 
to reduce the risks to societies posed by climate change. 
 
Finally, successfully implementing policies that lead to changing diet and travel behaviour, 
for example, can facilitate a societal change to a healthier, more environmentally conscious 
life-style. This, in turn, can result in further health and environmental benefits, on top of 
those estimated in our analysis. 
. 
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Table 1. Aggregate Health and Macroeconomic Effects  2010 
prices)
  Individual Scenarios   
Combined 
Scenario 
Healthy 
Diet 
Active 
Travel 
Housing 
Insulation   
Public Budget Net costs averted 
1
 2,435 15,010 -37   17,408 
Social Security Costs Averted 
1
 -716·4 -911·6 -80·4   -1,708·5 
  - Social Security Costs Averted (labour force) 11·8 123·5 17·6 
 
152·9 
  - Social Security Costs (dependents) 728·2 1,035·1 98·1 
 
1,861·4 
Healthcare Net Costs Averted 
1
 3,151·9 15,921·8 43·0   19,116·6 
Population increase (accumulated years)
2
 48,948 95,174 10,375   154,496 
Labour Force increase (accumulated years)
2
 184,669 256,229 24,238  465,135 
YLD (accumulated years)
2
 12,014 110,906 8,867   131,788 
  - Working age change 4,554 49,083 6,927 
 
60,564 
      - Labour force change 3,322 35,204 4,938 
 
43,464 
  - Dependents change
3
 7,460 61,823 1,940 
 
71,224 
YLL (accumulated years)
2
 184,669 256,229 24,238   465,135 
  - Working age change 62,635 83,106 7,544 
 
153,286 
      - Labour force change 45,626 59,970 5,436 
 
111,032 
  - Dependents change
3
 122,033 173,122 16,694 
 
311,849 
NB: 
1
 Net Present Value over 2011-2030 (2010 prices); 
2
 Accumulated population and work-years over 
2011-2030 without discounting; 
3 
Dependents are defined as members of the population outside 
working age (mostly those surviving into retirement). 
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Table 2. Health-related Macroeconomic Effects 
  
Per capita GDP 
(£; 2010 prices)
 1
   
GDP                                                           
(£million; 2010 prices)†
,1
 
  2015 2020 2030 NPV (2011-2030) 
All Health outcomes Combined 
Scenarios 
-0•90 6•58 23•91 
  
23,960 
All Healthy Diet Scenario health 
outcomes  
-1•72 -0•57 1•85 
  4,658 
All Active Travel Scenario health 
outcomes  
0•75 7•19 22•67 
  18,854 
All House Insulation Scenario 
health outcomes  
0•06 -0•04 -0•60 
  
447 
 
NB: 
1
 Net Present Value over 2011-2030 (2010 prices); † GDP gains can be posi;ve even when per 
capita GDP gains are negative because of population growth. 
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Figure 1: Annual discounted GDP of individual scenarios - effects on GDP of the health co-benefits in the three scenarios
1
 
  
1
 Note: the plots in Figure 1 are on different scales. The economic impact attributable to health effects in the housing intervention are not directly comparable with the 
scenarios for the other sectors because the underlying assumptions are so different, especially in relation to the time course of implementation.  The irregular shape of 
the insulation plot is due to the common mental disorder health effects described in the paper.  The health effects are phased to correspond with a program of 
investment in home insulation/ventilation (which is not modelled in this paper).  The relatively small health benefits for this scenario combined with the conservative 
assumption that the CMD impact was assumed to apply for only the first season following exposure makes the irregular shape more pronounced. 
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Appendix A: detailed description of scenarios modelled 
 
Active travel scenario 
The objective of the ‘active travel’ scenario is primarily to calculate the health-related 
economic benefits that would result from increased walking and cycling in urban England 
and Wales.  Our previous studies reported in The Lancet suggested that a permanent 35% 
reduction in urban motorized vehicle use is required to make a proportionate contribution 
towards meeting specific GHG targets outlined by the UK’s Climate Change Committee, and 
this reduction in urban vehicular transportation would yield a complementary increase in non-
motorized physically active transportation modes, with associated health benefits. In this 
paper we focus on the economic impact of the health co-benefits of increased active travel 
and do not consider the overall costs of policies to reduce greenhouse gas emissions.  
 
In 2008, 38% of the total distance travelled by car in the UK was in urban areas (excluding 
urban motorways)1.  The overall effect will therefore be a 13·3% reduction (35% of 38%) in 
the total distance travelled by car in the UK.  Although people living in urban areas outside 
London drive more than those who live in London, much of this driving will not be in urban 
areas2. 
 
The health effects from the transportation scenario are generated from two main sources, 
including positive health effects from increased physical activity, and negative health effects 
from increased road accidents and injuries due to increased use of non-motorized active 
travel modes.  Based on the findings of a range of systematic reviews of the effects of 
sedentary lifestyle on health, previous work1 shows that increased active travel reduces the 
disease burden and premature deaths due to diabetes, Alzheimers disease, hypertensive heart 
disease, ischaemic heart disease (IHD), cerebrovascular disease, breast cancer, colorectal 
cancer and depression.    However, the increased number of pedestrians and cyclists will also 
increase the number of road traffic accidents, leading to higher injury rates, including short-
term and long-term intracranial injuries and spinal cord injuries. 
 
Health effects associated with each of the above diseases and injuries were determined by the 
WHO comparative risk assessment approach1,3,4, and distributed in this analysis over a 20 
year horizon (see Appendix B ). The resulting dynamic patterns of health effects, including 
Years of healthy Life lost due to Disability (YLD) and Years of Life Lost (YLL), see 
Appendix C for specific values, were used to derive: (1) changes in the effective labour force 
(based on reduced YLD and YLL for the working age population corrected for gender-
specific labour market participation rates); and (2) changes in social security transfers 
including reduced labour market payments (based on reduced YLD for the working age 
population) and increased pension payments (based on reduced YLL for the old-age 
population). In addition, changes in healthcare costs were measured on the basis of actual 
incidence numbers and details of the calculation of these healthcare costs are provided in the 
companion paper2. The two types of health interventions (increased walking and cycling and 
increased road traffic accidents), together with the healthcare costs constitute the full range of 
‘active travel’ scenario shocks which are reported in this paper. 
 
                                                                 
1http://www.dft.gov.uk/pgr/statistics/datatablespublications/roads/traffic, accessed 19/01/12 
2
 Travel in Urban and Rural areas, Personal Travel Factsheet – March 2010 
http://webarchive.nationalarchives.gov.uk/+/http://www.dft.gov.uk/pgr/statistics/datatablespu
blications/personal/ntsfactsheets/NTSTravelinUrbanRuralareas.pdf, accessed 19/01/12  
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Housing insulation/ventilation scenario 
As for the active travel scenario, the health co-benefits from housing insulation were based 
on a GHG reduction strategy but only the health effects are modelled. The health effects 
modelled are assumed to result from a strategy to reduce GHG emissions through increased 
home insulation, improved air-tightness and mechanical ventilation with heat recovery 
(MVHR is installed in the 20 % of dwellings which are the most tightly sealed) together with 
fuel switching. As for the active travel scenario many of the health effects were determined 
by the WHO comparative risk assessment approach as outlined elsewhere.4 However, the 
effects modelled in the housing scenario  included YLL benefits for cardiopulmonary disease 
from exposure to PM2.5, lung cancer from exposure to PM2.5, cardiovascular disease from 
exposure to cold and lung cancer from exposure to radon and YLL harms from 
cerebrovascular disease from exposure to environmental tobacco smoke (ETS) and, 
ischaemic heart disease from exposure to ETS.  In addition there were YLD harms for asthma 
from exposure to mould (see Appendix C for all YLL and YLD values). It was decided that, 
although no YLDs had been estimated in Wilkinson et al4 for diseases for which YLLs had 
been calculated, that YLDs should be included for these conditions to bring the analysis in 
line with those in the other sectors.  We used the ratio of YLLs to YLDs from the WHO 
Global Burden of Disease to estimate YLDs corresponding to the YLLs.  We also added 
estimates for reduction in the prevalence of common mental disorder, using the limited 
evidence from observational studies. Our interpretation of that evidence was that a 0.4 degree 
Celsius rise in temperature (the average increase under the model assumptions) would result 
in a 4% relative reduction in CMD prevalence, a benefit which we conservatively assumed 
would apply in the winter period for only the first year after the intervention. In order to 
calculate the healthcare savings from reducing disease burden, we assumed the percentage 
reduction in YLDs was equivalent to a percentage reduction in cases (-0·02% for Asthma).  A 
lag of 20 years was assumed between the introduction of insulation and the full reduction in 
disease burden.  Annual costs of treatment were then multiplied by the total number of cases 
to obtain an estimate of annual costs averted. Future costs were discounted at 3·5%.  
 
Healthy diet scenario 
The health benefits, like the other scenarios, are based on a GHG reduction strategy but only 
the health co-benefits are considered in this paper. The GHG reduction strategy is to modify 
current eating patterns which contain large amounts of animal-source foods that have high 
associated GHG emissions (for example because of the emission of the potent GHG methane 
from ruminants) and are high in saturated fat. A 30% reduction in the production of processed 
meat and dairy products (in order to achieve GHG emission targets) is assumed and it is 
assumed further that the reduction in consumption of dietary saturated fat and cholesterol 
takes place in the initial period, i.e. without the need for gradual phasing-in of the scenario. 
 
Health benefits are assumed to occur through reduced consumption of livestock-related food 
products which would be assumed to yield a health co-benefit by reducing the burden of IHD 
and stroke.  YLLs and YLDs were calculated from [3] for ischaemic heart disease from 
exposure to saturated fat, and YLLs for stroke from exposure to dietary cholesterol were also 
used and are presented in Appendix C.  As for the housing insulation scenario, the YLDs for 
stroke were calculated using the YLL and YLD ratios from the WHO Global Burden of 
Disease and we calculated health care savings using the same method as described in the 
Housing Insulation scenario.  However, we assumed a five year time lag for full effects of 
dietary change on IHD and stroke in this scenario. 
 
Adjustment for life expectancy and duration 
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As outlined above, and in the main article, the estimates of YLL and YLDs used in the 
modelling scenarios were adjusted to capture only those effects which occur within the 20 
year period of the model.  The sources of these estimates are tabulated in Appendix C and 
were primarily the original Lancet articles 200910-15 or were adjusted from the relative burden 
of YLLs vs YLDs as outlined in WHO Global Burden of Disease.  However, to illustrate the 
effect of this adjustment the raw (adjusted) YLL and YLD values are tabulated in Table A 
and compared with the age and duration adjusted values. 
 
 
 
Table A: Comparison of raw YLDs and YLLs with those adjusted for life expectancy and duration. 
  YLD YLL YLD (Adjusted
*
) YLL (Adjusted
 *
) 
Healthy Diet Related Diseases         
Ischaemic Heart Disease (saturated fat) 9,994 167,466 11,595 182,136 
Stroke (cholesterol) 9,994 2,264 420 2,533 
Active Travel Related Diseases         
Diabetes (Activity) 15,323 7,006 17,136 7,265 
Alzheimer (Activity) 27,987 7,212 29,481 7,474 
Hypertensive Heart Disease (Activity) 657 4,697 820 5,501 
Ischaemic Heart Disease (Activity) 18,835 138,451 21,850 150,578 
Cerebrovascular Disease (Activity) 19,958 65,329 23,451 73,133 
Breast Cancer (Activity) 3,089 21,457 3,203 18,198 
Colorectal Cancer (Activity) 857 5,526 891 5,404 
Depression (Activity)          14,746                36 18,672 24 
Long-term Intracranial Injuries (Traffic Related) 1,655 6,849 -949 -3,762 
Short-term Intracranial Injuries (Traffic Related) 4,027 16,665 -4,341 -8,865 
Spinal Cord Injuries (Traffic Related) 827 3,424 -600 -1,907 
House Insulation/ventilation  Related Diseases         
Cerebrovascular Disease (ETS) -903 -5,723 -491 -2,960 
Ischaemic Heart Disease (ETS) -745 -7,903 -403 -4,006 
Cardiopulmonary Disease (PM2.5) 5,267 55,860 2,848 28,309 
Lung Cancer (PM2.5) 120 7,980 15 921 
Cardiovascular Disease (cold) 520 4,480 282 2,283 
Lung Cancer (Radon) -40 -2,676 -5 -309 
Asthma (Mould) -933 
 
-523 
 
Depression (Cold) 
 
  7,144   
*
 ‘Adjusted figures are those effects which are estimated to occur within the 20 year time period of the 
model and are calculated from the duration value for YLDs and life expectancy for YLLs  
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Appendix B: detailed health impact analysis 
 
Health effects 
Health effects in the model (benefits and harms) were captured in three ways. 
1. Changes in labour supply: by estimating changes in YLD (morbidity) and YLL 
(mortality) in those of working age (15-64) the supply of labour available for 
productive use in the economy was adjusted. 
2. Healthcare savings: estimates of the change in healthcare savings/expenditure were 
estimated2 and, since a revenue-neutral government budget closure is assumed, the 
reduction in government expenditures translates into a reduced public sector deficit 
which lowers government crowding-out and increases savings for productive private 
investment purposes.  
3. Social security: changes in social security payments from changes in working age 
morbidity and retirement age mortality are calculated and leads to reduced 
government crowding-out and increased savings for productive private investment 
purposes in a similar way to healthcare savings (as above) 
 
Immediate vs. staged implementation 
YLL and YLD estimates from GHG reduction policies have been previously reported2,3,4.  
These estimates assume an immediate intervention and calculate reductions in disease 
burdens due to changes in exposure to various factors (outlined in the scenario specific 
descriptions and Appendix A).  As a result, we assume immediate implementation of a 
healthy diet and active transport intervention to accomplish the necessary changes in 
consumption and transportation use and so assume that the health benefits presented in the 
previous Lancet papers would be realised.  In the case of the home insulation/ventilation, 
although we only focus on the health effects rather than the wider abatement scenario, the 
investment required in construction and the work that would need to be carried out is too 
great for the full abatement intervention to be applied immediately and therefore a staged 
implementation of the health effects for this scenario is used. 
 
Lagging health effects 
In addition to this, an adjustment has been made to the health effects to account for the 20 
year period of the model, since the YLL and YLD values previously reported do not account 
explicitly for the timing of those health benefits/harms.  Health effects for all interventions 
(except for road traffic accidents) have been staggered using a sigmoid function (defined by 
the cumulative distribution function of a normal distribution) to account for both the delay 
before health effects start to accrue  and the lag time until the full health effects are realised.  
The timing of the delay and lag is determined by the parameters of the sigmoid function (i.e. 
the mean and standard deviation of the normal distribution) and these are presented in the 
assumptions table (Appendix C). A more comprehensive modelling approach for phasing the 
co-benefits would require re-calculation of the co-benefits using time-varying disease risk 
profiles within multi-state life tables5. However, we used the co-benefits as calculated from 
the previous studies.2,3,4 In the case of road traffic accidents, it is assumed that accidents 
occur at a constant rate over time. 
 
20 year cut off 
A further adjustment to the YLL and YLD was also made since the CGE model is run over a 
20 year time period.  For this reason the YLL values had to be adjusted, taking account of life 
expectancies, to remove any health effects that would be experienced beyond the timescale of 
the model.  Similarly, YLD values were adjusted to account for durations that extend beyond 
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the scope of the model timescale.  Finally, the health effects were disaggregated by age and 
sex using WHO Global Burden of Disease incidence data6 and the CGE model utilised the 
UK ONS mid-year population projections3 and employment statistics to calculate the 
proportion of working age adults to which the health effects apply in each period. 
 
CRA Adjustment 
Since the standard comparative risk assessment method (that we used in the previous Lancet 
studies) is a static tool for estimating health effects it does not account for the increasing 
burden of illness that is expected to occur over the 20 year simulation period.  In order to 
account for this shortcoming, WHO projections of mortality and burden of disease 2004-
203045 were used to estimate annual increases in our YLL and YLD estimates.  Standard 
DALY estimates for Europe were undiscounted and average rates of change for the 2010-
2015 and 2016-2030 periods were calculated for each health effect and used to adjust the 
phased YLL and YLDs.  The rates used are tabulated in table B1. 
  
                                                                 
3
 For a detailed explanation of the methodology used in national population projections, see 
papers available on the National Population Projections section of the ONS website at 
www.statistics.gov.uk/StatBase/Product.asp?vlnk=8519  
4
 http://www.who.int/healthinfo/global_burden_disease/projections/en/ 
5
 Mathers C and Loncar D, Projections of Global Mortality and Burden of Disease from 2002 to 2030.PLoS Med. 
2006 Nov;3(11):e442 
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Table B1: Percentage changes in health effects over time 
2008 (un-
discounted 
DALYs) 
2015 (un-
discounted 
DALYs) 
2030 (un-
discounted 
DALYs) 
Growth 
Rate 
'08-'15 
Growth 
Rate 
'15-'30 
All Healthy Diet Related Diseases 
   Ischaemic Heart Disease (saturated fat) 18,432,764 20,635,108 27,095,621 1•6% 1•8% 
Stroke (cholesterol) 10,478,600 12,044,720 16,750,335 2•0% 2•2% 
All Active Travel Related Diseases     
Diabetes (Activity) 2,969,258 3,730,546 5,643,687 3•3% 2•8% 
Alzheimer (Activity) 3,699,256 4,960,683 9,075,682 4•3% 4•1% 
Hypertensive Heart Disease (Activity) 1,215,580 1,419,836 2,167,223 2•2% 2•9% 
Ischaemic Heart Disease (Activity) 18,432,764 20,635,108 27,095,621 1•6% 1•8% 
Cerebrovascular Disease (Activity) 10,478,600 12,044,720 16,750,335 2•0% 2•2% 
Breast Cancer (Activity) 1,934,588 2,404,857 3,553,682 3•2% 2•6% 
Colorectal Cancer (Activity) 2,126,074 2,629,208 4,016,609 3•1% 2•9% 
Depression (Activity) 9,432,559 11,531,693 18,073,759 2•9% 3•0% 
Long-term Intracranial Injuries (Traffic Related) 3,833,261 4,122,512 4,956,999 1•0% 1•2% 
Short-term Intracranial Injuries (Traffic 
Related) 3,833,261 4,122,512 4,956,999 1•0% 1•2% 
Spinal Cord Injuries (Traffic Related) 3,833,261 4,122,512 4,956,999 1•0% 1•2% 
All House Insulation/Ventilation Related Diseases     
Cerebrovascular Disease (ETS) 10,478,600 12,044,720 16,750,335 2•0% 2•2% 
Ischaemic Heart Disease (ETS) 18,432,764 20,635,108 27,095,621 1•6% 1•8% 
Cardiopulmonary Disease (PM2•5) 18,432,764 20,635,108 27,095,621 1•6% 1•8% 
Lung Cancer (PM2•5) 3,613,493 4,430,858 6,472,929 3•0% 2•6% 
Cardiovascular Disease (cold) 37,444,528 42,134,289 56,174,901 1•7% 1•9% 
Lung Cancer (Radon) 3,613,493 4,430,858 6,472,929 3•0% 2•6% 
Asthma (Mould) 1,456,336 1,730,207 2,514,172 2•5% 2•5% 
Depression (Cold) 9,432,559 11,531,693 17,029,223 2•9% 2•6% 
 
 
 
Healthcare Savings 
Estimation of scenario and disease specific changes in healthcare savings are documented in 
the accompanying paper19. In that paper we discuss the possibility that the costs averted could 
either be reinvested in the NHS to buy additional health care or taken as savings by the 
Government. In this analysis we assume they are taken as savings. These changes are 
imposed on the model but because of the revenue-neutral government budget assumption, the 
flexible tax rate ensures that government revenues remain unchanged. Consequently, when 
current expenditures are reduced, the budget deficit is also reduced and overall savings are 
increased.  These increased savings can then be used for productive investment. 
 
Social Security 
In a similar way, once adjusted as described above, the health effects were used to estimate 
the reductions in benefit payments (morbidity changes) and increases in pension payments 
(mortality changes) that result from each scenario and resulting changes in social security 
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payments are reported in the results section.  Changes in benefit payments were calculated as 
the change in YLDs for those of working age (15-64), multiplied by the yearly benefit 
payment estimate (see Appendix C).  Changes in pension payments were calculated as 
changes in YLLs for those of retirement age (over 65) multiplied by the yearly pension 
payment estimate (see Appendix C). 
 
Table B2 demonstrates the contributions to the economic benefits of each of the health 
outcomes. Reductions in disease burden from Ischaemic Heart Disease (IHD), Dementia and 
Diabetes make the largest contributions to health care savings, while reduced disease burden 
from IHD, Cerebrovascular disease and depression make the largest contributions to the 
labour force. In the case of social security costs, IHD and Cerebrovascular disease make 
substantial contributions. 
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Table B2 Disease-specific Health - Related Macroeconomic Effects 
  
Scenario 
  
Changes in Morbidity & Mortality          
 (Accumulated; 2011-2030) 
  
Net Social Security & 
Healthcare costs            
(£million; 2010 prices)
1
   
Per capita GDP 
(£; 2010 prices)
 1
   
GDP                  
(£million; 
2010 prices)† 
1
 
    YLD YLL Labour force2 Dependents3 
 
Social Security Healthcare 
 
2015 2020 2030   NPV (2011-2030) 
Combined All Combined Diseases 131,788 465,135 154,496 383,073  1,424•2 -19,116•6  -0•90 6•58 23•91  23960•2 
Healthy Diet All Healthy Diet related Diseases 12,014 184,669 48,948 129,494  597•2 -3,151•9  -1•72 -0•57 1•85  4658•8 
 
Ischaemic Heart Disease (saturated fat, 
dietary cholesterol) 11,595 182,136 48,265 127,485  588•9 -3,095•5  -1•70 -0•58 1•81  4577•8 
 
Stroke (dietary cholesterol) 420 2,533 683 2,008 8•3 -56•4 -0•02 0•01 0•04 80•9 
Active Travel All Active Travel related Diseases 110,906 256,229 95,174 234,945  759•9 -15,921•8  0•75 7•19 22•67  18853•9 
 Diabetes (Active travel) 17,136 7,265 9,189 11,681  -1•2 -7,598•1  0•75 3•70 13•45  7146•1 
 Alzheimer (Active travel) 29,481 7,474 6,981 27,207 10•7 -260•4 0•00 0•00 0•97 386•1 
 
Hypertensive Heart Disease (Active 
travel) 820 5,501 1,588 4,142 17•4 0•0 -0•06 -0•07 -0•10 49•8 
 Ischaemic Heart Disease (Active  travel) 21,850 150,578 43,304 112,998 476•8 -4,698•5 -0•57 1•38 5•00 6368•0 
 Cerebrovascular Disease (Active travel) 23,451 73,133 22,352 65,572 232•4 -1,550•5 -0•23 0•43 1•19 2504•7 
 Breast Cancer (Active travel) 3,203 18,198 6,843 11,513 44•5 -247•4 0•00 0•00 -0•38 375•9 
 Colorectal Cancer (Active travel) 891 5,404 1,504 4,218 16•8 -70•2 0•00 0•00 -0•22 86•9 
 Depression (Active travel) 18,672 24 11,907 1,981 -35•0 -2,146•7 1•28 2•45 3•82 3138•2 
 Long-term Intracranial Injuries (Traffic) -741 -2,937 -1,907 -1,081 -1•7 61•7 -0•04 -0•06 -0•09 -159•4 
 Short-term Intracranial Injuries (Traffic) -3,390 -6,922 -5,388 -2,960 -0•6 263•2 -0•17 -0•30 -0•46 -568•8 
 Spinal Cord Injuries (Traffic) -468 -1,489 -1,198 -325 -0•2 325•0 -0•20 -0•34 -0•49 -473•0 
House Insulation 
All House Insulation related  
Diseases 8,867 24,238 10,375 18,634  67•1 -43•0  0•06 -0•04 -0•60  447•7 
 Cerebrovascular Disease (ETS)
4
 -491 -2,960 -788 -2,358  -9•6 2•8  0•01 0•03 0•08  -29•9 
 Ischaemic Heart Disease (ETS)
 4
 -403 -4,006 -1,099 -2,901 -12•7 7•8 0•01 0•04 0•10 -45•9 
 Cardiopulmonary Disease (PM2•5) 2,848 28,309 7,095 21,312 93•3 -72•9 -0•11 -0•28 -0•74 311•3 
 Lung Cancer (PM2•5) 15 921 243 607 2•8 0•0 0•00 0•00 -0•09 9•9 
 Cardiovascular Disease (cold) 282 2,283 641 1,686 7•2 26•1 -0•01 -0•04 -0•11 -0•9 
 Lung Cancer (Radon) -5 -309 -82 -203 -1•0 0•0 0•00 0•00 0•03 -3•4 
 Asthma (Mould) -523 0 -189 -261 0•5 3•0 0•00 -0•01 -0•02 -10•6 
 Depression (Cold) 7,144 0 4,552 753 -13•6 -9•7 0•16 0•22 0•14 216•9 
NB: 
1
 Net Present Value over 2011-2030 (2010 prices); 
2
 Accumulated work-years over 2011-2030 without discounting; 
3 
Dependents are defined as members of the population outside working 
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age (mostly those surviving into retirement), 
4
IHD and stroke increase because of the increased air ;ghtness in some homes † GDP gains can be posi;ve even when per capita GDP gains are 
negative because of population growth 
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Appendix C: Assumptions Table 
 
Assumption Value source 
UK population 
(by age) 
Mid-year population estimates 2004 to 2008, 
and 2008-based population projections 2009 to 
2030, by single year of age and sex in the 
United Kingdom 
http://www.statistics.gov.uk/ 
populationestimates/ 
flash_pyramid/default.htm  
 Health Assumptions: General  
Health effect 
implementation 
Agriculture and transport: immediate 
exposure change,  sigmoid curve or linear 
distribution as outlined below 
Insulation: as above but time distributed 
health effects are divided by 20 and introduced 
linearly over time (benefits/harms beyond 2030 
are not included) 
 
Time effects 
distributed as 
sigmoid curve 
(cumulative 
distribution 
function of a 
normal 
distribution) 
with 
parameters  2 
years (mean) 
and 0·9 years 
(standard 
distribution) 
Ischaemic heart disease 
Stroke 
Alzheimers disease 
Hypertensive heart disease 
Cerebrovascular disease 
Depression 
Trachea, bronchus, lung cancers 
Lower respiratory infections 
Upper respiratory infections 
Inflammatory heart diseases 
Chronic obstructive pulmonary disease 
Asthma 
Other respiratory diseases 
 
Time effects 
distributed as 
sigmoid -curve 
with 
parameters 3·2 
years and 1·2 
years, 
respectively 
Diabetes  
Time effects 
distributed as 
sigmoid curve 
with 
parameters  17 
years and  1 
year, 
respectively 
Breast cancer 
Colorectal cancer 
Lung Cancer 
 
Linear 
(constant) 
distribution of 
health effects 
All road traffic crashes  
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Pension 
payment 
£5312 per year http://www.direct.gov.uk/en/ 
Pensionsandretirementplanning/ 
StatePension/DG_188551 
Benefit 
payment 
£ 3146 per year http://www.timesonline.co.uk/ 
tol/money/reader_guides/ 
article5572594.ece 
Life 
expectancy (for 
YLL 
adjustment) 
See source Murray CJL, Lopez AD (1996) 
The global burden of disease  
Disease 
duration (for 
YLD 
adjustment) 
See source Murray JL & Lopez AD (1996) 
Global health statistics. WHO. 
Prevalence (for 
YLL and YLD 
distribution by 
age) 
See source Murray JL & Lopez AD (1996) 
Global health statistics. WHO. 
 Health Assumptions: Agriculture 
(Exposure: Response) 
 
YLL 167466 (Saturated fat: IHD) 
2264 (Cholesterol: stroke) 
Friel S, Dangour AD, et. al. 
Lancet 2009 
Scaled by ONS UK population 
model underlying CGE model 
YLD 9994 (Saturated fat to IHD) Friel S, Dangour AD, et. al. 
Lancet 2009 
Scaled by ONS UK population 
model underlying CGE model 
YLD 9994 (Cholesterol: stroke) Calculated relative to YLLs for 
Cholesterol: stroke using 
cerebrovascular disease ratio of 
YLLs to YLDs from WHO 
Global Burden of Disease 
 Health Assumptions: Transport (Exposure: 
Response) 
 
YLL 7,006 ( Physical activity:  Diabetes) 
7,212 ( Physical activity: Alzheimer) 
4,697 ( Physical activity: Hypertensive heart 
disease) 
138,451 ( Physical activity: Ischaemic Heart 
disease) 
65,329 ( Physical activity: Cerebrovascular 
disease) 
21,457 ( Physical activity: Breast cancer) 
5,526 ( Physical activity: Colorectal cancer)  
 
-22829 ( Urban road accidents broken into: 
6,849 Fractured skull or intracranial injury 
(30%)  
Woodcock et. al. Lancet ,2009.. 
Scaled by England and Wales 
urban population model from 
Jarrett, et. al, of 45,431,777 
(settlements of 20,000 residents 
or more, representing 
approximately 82% of the 
population of England and 
Wales) 
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16,665 Extremity injuries, Abdominal injury, 
Pelvic injuries & Thoracic injury (73%)  
3,424 Spinal cord injury (15%)) 
   
YLD 15,323 ( Physical activity:  Diabetes) 
27,987 ( Physical activity: Alzheimer) 
657 ( Physical activity: Hypertensive heart  
disease) 
18,835 ( Physical activity: Ischaemic Heart 
disease) 
19,958 ( Physical activity: Cerebrovascular 
disease) 
3,089 ( Physical activity: Breast cancer) 
857 ( Physical activity: Colorectal cancer) 
    
-6,509 ( Urban road accidents broken into: 
1,655 Fractured skull or intracranial injury 
(30%)  
4,027 Extremity injuries, Abdominal injury, 
Pelvic injuries & Thoracic injury (73%)  
827 Spinal cord injury (15%))  
Woodcock et. al.,Lancet 2009 
Scaled by England and Wales 
urban  population model from 
Jarrett, et. al, of 
45,431,777(settlements of 
20,000 residents or more, 
representing approximately 
82% of the population of 
England and Wales) 
 Health Assumptions: Insulation/ Ventilation  
(Exposure: Response) 
 
YLL -5723 (ETS: Cerebrovasular disease) 
-7903 (ETS : Ischaemic Heart disease) 
55,860 (PM2.5: Cardiopulmonary disease) 
7980 (PM2.5: Lung Cancer) 
4480 (Cold: Cardiovascular disease) 
-2676 (Radon: Lung Cancer) 
Wilkinson et. al. 2009 
Scaled by ONS UK population 
model underlying CGE model 
YLD -933 (Mould: Asthma) Wilkinson et. al. 2009 
Scaled by ONS UK population 
model underlying CGE model 
YLD -903 (ETS: Cerebrovasular disease) 
-745 (ETS : Ischaemic Heart disease) 
5267 (PM2.5: Cardiopulmonary disease) 
120 (PM2.5: Lung Cancer) 
520 (Cold: Cardiovascular disease) 
-40 (Radon: Lung Cancer) 
Calculated relative to YLLs 
cerebrobascular disease and 
ischaemic heart disease (both 
IHD and cardiopulmonary 
disease) ratio of YLLs to YLDs 
from WHO Global Burden of 
Disease 
 Other Assumptions  
GDP growth 
and inflation 
(for pre-
simulation) 
See source World Economic Outlook 
Database (accessed online 18/7-
2011) 
All Healthcare 
Costs/Savings 
 Jarrett et. al. (accompanying 
paper) 
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Appendix D: Detailed description of CGE model 
 
The scenarios were implemented using an economy-wide dynamically-recursive Computable 
General Equilibrium (CGE) model. The model was constructed on the basis of the ‘IFPRI 
Standard Model’20– a well known and widely applied static model framework which has 
recently been used in health applications by some of the authors16. The standard model is a 
static multi-sector simulation model with multiple production sectors and goods markets for 
individual sectors such as agriculture, manufacturing and services, including health. There are 
four main forms of economic ‘agents’ in the model: firms, consumers, government, and 
foreign agents. Firms seek to combine resource inputs to maximize profits, while consumers 
aim to allocate their income between consumption and savings in order to maximize their 
welfare. Production technologies are assumed to consist of nested Leontief functions 
(intermediate inputs) and Constant Elasticity of Substitution (CES) functions (primary factor 
inputs) with a CES function top-nest, while consumer welfare are based on utility functions 
which consists of nested Stone-Geary utility functions for non-energy goods and a CES 
function top-nest which allows for (low) substitution between energy demand and composite 
non-energy demand. The government levy taxes, distribute benefits, and purchase goods 
directly, while foreign agents interact with domestic agents through goods trade (firms), 
unrequited transfers and foreign lending and borrowing (households and government). 
Imperfect substitution is assumed in goods trade through an Armington (CES) specification 
on the import side and a Constant Elasticity of Transformation (CET) specification on the 
export side. 
 
A baseline CGE model is calibrated on the basis of data from a given year, and therefore 
replicates the economy at a specific time point. Specific impacts or policy interventions are 
then modelled as external ‘shocks’ to the economy, following which the model adjusts to the 
shocks and produces a new equilibrium solution. In the current case, the model was calibrated 
on the basis of a 2004 Social Accounting Matrix (SAM) for the UK, which was taken from 
the GTAP database version 7.9 The original data-set contained 57 sectors, including 14 
agricultural sectors, 28 primary extraction and manufacturing sectors, and 15 service sectors. 
This data-set was, subsequently, extended to account, separately, for household demand and 
production of private transportation services (three sectors) and private heating services (two 
sectors). Finally, the data-set was aggregated to 22 sectors including three agricultural 
accounts (‘crops’, ‘livestock’, and ‘forestry and fishery’), seven primary extraction and 
manufacturing sectors (including ‘processed meat and dairy products’ and ‘fossil fuels’), 
seven service accounts (including ‘energy’, land transportation’, and ‘Public administration, 
defence, education, health’), and five sectors relating to private transportation and heating 
services. The level of aggregation was chosen as a trade-off between retaining sufficient 
detail for meaningful analysis of the different scenarios and minimizing the complexity of the 
model. 
Following the calibration of the static model, factor stock updating equations were added, 
including labour growth and capital accumulation equations, to turn the static model into an 
enhanced dynamically-recursive CGE model framework. In order to measure the future 
economic impact of the above scenarios, it was necessary to run a pre-simulation to target 
historical UK growth patterns over the period 2004-2010. Focus was on targeting of nominal 
demand aggregates (private and government consumption, gross fixed capital formation and 
stock changes, and export and import aggregates), as well as nominal and real GDP. In this 
way, the pre-simulation established 2010 as the base year for undertaking meaningful 
simulations of the GHG emission reduction scenarios over the period 2011-2030. In order to 
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measure the simulation impact of the three scenarios, it was, furthermore, necessary to 
establish a counterfactual growth path over the period 2011-2030. The expected future 
growth path was modelled on the basis of the historical UK growth performance during 1990-
2010, which included an average 5·1% nominal GDP growth rate and an average 2·1% real 
GDP growth rate. The targeting of nominal and real GDP growth rates were achieved by 
letting the GDP deflator act as price numeraire, and by allowing the model to determine the 
underlying expected change in Total Factor Productivity (TFP) in the UK economy over the 
projection horizon. 
 
The implementation of the dynamically-recursive CGE model was based on a neo-classical 
model closure. This implies that prices clear all domestic markets for goods and production 
factors (with full employment of available factor supplies), and that balance of payments 
equilibrium is ensured through adjustments to the real exchange rate. General equilibrium, 
furthermore, requires that all institutional budget accounts are balanced, including current and 
capital accounts for all agents including private households, firms, and the government. 
Balance on current accounts is in all cases ensured through adjustments to savings, while 
balance on the aggregate savings-investment account is ensured through the specification of a 
standard savings-driven investment closure. Additional closure rules are applied to the 
government’s current account in order (1) to ensure that the government budget remains a 
constant fraction of absorption in the UK economy over time, and (2) to ensure that the 
government budget is not expanded by the model shocks within a given year. The former 
target is achieved by adopting a so-called balanced macro closure where government 
consumption is modelled as a fixed share of absorption, while the latter target is achieved by 
adopting a so-called revenue-neutral government budget closure where total government 
revenues are fixed by allowing household tax rates to vary endogenously. The balanced 
macro closure is only applied in the derivation of the counterfactual growth path, while 
nominal government consumption is kept fixed at the counterfactual government 
consumption growth path (net of healthcare savings) in the simulation of the individual 
scenarios. 
 
The implementation of the different scenarios involves health effects of the individual 
emission reduction strategies. Estimated healthcare savings are, in each case, deducted from 
government consumption, and this leads to a lower government current budget deficit and 
increased availability of domestic savings for investment purposes. Similarly, estimated 
social security savings (due to reduced labour market benefits) and social security costs (due 
to increased pension payments) are in each case deducted/added to government transfers to 
households. Again, this leads to a lower/higher government current budget deficit and 
increased availability of domestic savings for investment purposes. Finally, health benefits in 
the form of increases in the effective labour force (due to scenario-specific reductions in 
YLDs and YLLs for the working age population) are implemented through adjustments to 
total labour supplies, where the supplies of skilled and unskilled labour are assumed to 
expand proportionally. The health shocks outlined above were all introduced with a time lag 
and with staggered effects, to account for disease-specific differences in the dynamic pattern 
of the realization of the health effects (see Appendix B ).   
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Appendix E: Sensitivity Analyses 
 
Production Elasticities 
In order to assess how the health-related labour force impact affects production differently 
depending on the degree of substitutability of labour for other production factors, we 
performed a sensitivity analysis on the elasticity of factor substitution.  A high value of this 
elasticity causes a larger change in the ratios between different factor quantities in response to 
changes in relative factor prices, conversely a low value of this elasticity suggests that the 
ratios of factor quantities are relatively inelastic to changes in factor prices, so a change in 
factor prices will yield a smaller change in the relative factor quantities used in production. 
 
In terms of specific parameter values, an elasticity of factor substitution of less than one 
implies that factors are complements to each other, whereas a value greater than one implies 
that they are substitutes.  The default value for this elasticity used in the main scenarios 
presented in this article is 0.8.  For our sensitivity analysis we have used the values 0.5, 1, 1.5 
and 2 to cover a range of substitution possibilities. 
 
Table E1 shows that the overall GDP gains are smaller for low production elasticities and 
larger for high elasticities.  For the combined scenario, the GDP gain is reduced by over 
£830m (3.5%) if the production elasticity is reduced to 0.5 and increased by £1.84bn (7.7%) 
if the elasticity is increased to 2.  This shows that the ability of the economy to make 
productive use of the labour gains will be influential in determining the overall economic 
impact of the health-related labour force gains.  If the economy is able to absorb the 
additional labour supply, the health-related labour supply gains will have a positive effect on 
the economic impact by increasing production, reducing the unemployment rate and reducing 
social security payments.  Conversely, if the economy is less able to absorb the increased 
labour supply these gains will be reduced. 
 
Table E1: Sensitivity of  Aggregate Health Effects (NPV in 2010 prices) 
  Individual Scenarios   
 
Production 
Elasticity 
 
Healthy 
Diet 
Active 
Travel 
Housing 
Insulation 
Combined 
Scenario 
0•5 ΔGDP (2011-2030)
1
 4,588 18,077 466   23,130 
 
ΔGDP per capita (2015)
2
 -1•65 0•79 0•07   -0•79 
 
ΔGDP per capita (2020)
2
 -0•58 6•79 -0•02 
 
6•19 
 
ΔGDP per capita (2030)
2
 1•58 20•84 -0•57 
 
21•84 
0•8 
(Standard) ΔGDP (2011-2030)
 1
 4,659 18,854 448   23,960 
 
ΔGDP per capita (2015)
2
 -1•72 0•75 0•06   -0•90 
 
ΔGDP per capita (2020)
2
 -0•57 7•19 -0•04 
 
6•58 
 
ΔGDP per capita (2030)
2
 1•85 22•67 -0•60 
 
23•91 
1 ΔGDP (2011-2030)
 1
 4,691 19,245 438   24,374 
 
ΔGDP per capita (2015)
2
 -1•75 0•74 0•06   -0•96 
 
ΔGDP per capita (2020)
2
 -0•58 7•40 -0•04 
 
6•78 
 
ΔGDP per capita (2030)
2
 1•97 23•51 -0•62 
 
24•86 
1•5 ΔGDP (2011-2030)
 1
 4,757 20,024 419   25,200 
 
ΔGDP per capita (2015)
2
 -1•79 0•71 0•05   -1•03 
 
ΔGDP per capita (2020)
2
 -0•59 7•74 -0•06 
 
7•09 
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ΔGDP per capita (2030)
2
 2•20 25•10 -0•64 
 
26•65 
2 ΔGDP (2011-2030)
 1
 4,810 20,581 405   25,796 
 
ΔGDP per capita (2015)
2
 -1•82 0•69 0•05   -1•07 
 
ΔGDP per capita (2020)
2
 -0•60 7•93 -0•07 
 
7•26 
 
ΔGDP per capita (2030)
2
 2•38 26•39 -0•67 
 
28•09 
NB: 
1
 Net Present Value over 2011-2030 (millions £ in 2010 prices); 
2
 Net Present Value (£ in 
2010 prices) 
 
Half Active Travel Sensitivity 
As outlined in the previous lancet paper accompanying paper192, an additional scenario for 
the transport intervention has been generated which assumes half of the increase in walking 
and cycling estimated in the original scenario will be achieved in practice.  In order to 
estimate the macroeconomic impact of this reduced intervention the YLL and YLD series’ 
were halved and the reduced healthcare savings series from Jarrett et al2 were imported. 
 
Table E2 shows the results of this sensitivity analysis.  A comparison with Table B2 (the 
equivalent table for the original results) reveals that the YLL and YLD values for transport 
are halved with the exception of road traffic crashes where the YLLs and YLDs from the full 
active travel scenario are multiplied by a factor of -0.86 corresponding to the relative 
magnitudes of the incidence estimates in Jarrett et al2.  The healthcare savings are reduced to 
approximately 60-70% of their original magnitude (except for colorectal cancer where there 
is a smaller reduction and road traffic crashes where the -0.86 factor change in the YLLs and 
YLDs is mirrored).  Overall, there is a reduction of 30% in the NPV GDP gains for the 
transport intervention and a reduction of 25% in the NPV GDP gains for the combined 
scenario. Therefore the reduction in health co-benefits yields an approximately proportional 
reduction in NPV GDP gains. 
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Table E2 Disease-specific Health - Related Macroeconomic Effects- Half Active Travel 
  
Scenario 
  
Changes in Morbidity & Mortality          
 (Accumulated; 2011-2030) 
  
Net Social Security & 
Healthcare costs            
(£million; 2010 prices)
1
   
Per capita GDP (£; 2010 
prices)
 1
   
GDP                  
(£million; 2010 
prices)† 
1
 
    YLD YLL Labour force
2
 Dependents
3
 
 
Social Security Healthcare 
 
2015 2020 2030   NPV (2011-2030) 
Combined All Combined Diseases 
82,589 352,455 118,460 271,539  1,047•6 -13,929•5  -0•30 5•10 17•18  18026•3 
Healthy Diet All Healthy Diet related Diseases 
12,014 184,669 48,948 129,494  597•2 -3,151•9  -1•72 -0•57 1•85  4658•8 
 Ischaemic Heart Disease (saturated 
fat, dietary cholesterol) 11,595 182,136 48,265 127,485  588•9 -3,095•5  -1•70 -0•58 1•81  4577•8 
 Stroke (dietary cholesterol) 
420 2,533 683 2,008 8•3 -56•4 -0•02 0•01 0•04 80•9 
Active Travel All Active Travel related Diseases 
61,707 143,549 59,138 123,412  383•4 -10,734•7  1•35 5•70 15•94  12919•9 
 Diabetes (Active travel) 
8,568 3,632 4,595 5,840  -0•6 -4,791•4  0•46 2•32 8•46  4454•1 
 Alzheimer (Active travel) 
14,740 3,737 3,490 13,604 5•4 -181•2 0•00 0•00 0•60 210•5 
 Hypertensive Heart Disease (Active 
travel) 410 2,750 794 2,071 8•7 0•0 -0•03 -0•04 -0•05 24•9 
 Ischaemic Heart Disease (Active  
travel) 10,925 75,289 21,652 56,499 238•4 -2,808•5 -0•18 1•02 3•24 3675•0 
 Cerebrovascular Disease (Active 
travel) 11,726 36,567 11,176 32,786 116•2 -901•0 -0•07 0•33 0•79 1397•7 
 Breast Cancer (Active travel) 
1,602 9,099 3,421 5,756 22•3 -162•5 0•00 0•00 -0•10 202•4 
 Colorectal Cancer (Active travel) 
446 2,702 752 2,109 8•4 -24•1 0•00 0•00 -0•14 39•4 
 Depression (Active travel) 
9,336 12 5,953 990 -17•5 -1,304•4 0•81 1•47 2•24 1877•3 
 Long-term Intracranial Injuries 
(Traffic) 637 2,526 1,640 930 1•4 -53•3 0•03 0•06 0•08 137•6 
 Short-term Intracranial Injuries 
(Traffic) 2,915 5,953 4,633 2,546 0•5 -227•4 0•15 0•26 0•39 491•5 
 Spinal Cord Injuries (Traffic) 
403 1,281 1,031 280 0•2 -280•8 0•18 0•29 0•43 409•7 
House Insulation All House Insulation related  
Diseases 8,867 24,238 10,375 18,634  67•1 -43•0  0•06 -0•04 -0•60  447•7 
 Cerebrovascular Disease (ETS)
4
 
-491 -2,960 -788 -2,358  -9•6 2•8  0•01 0•03 0•08  -29•9 
 Ischaemic Heart Disease (ETS)
 4
 
-403 -4,006 -1,099 -2,901 -12•7 7•8 0•01 0•04 0•10 -45•9 
 Cardiopulmonary Disease (PM2•5) 
2,848 28,309 7,095 21,312 93•3 -72•9 -0•11 -0•28 -0•74 311•3 
 Lung Cancer (PM2•5) 
15 921 243 607 2•8 0•0 0•00 0•00 -0•09 9•9 
 Cardiovascular Disease (cold) 
282 2,283 641 1,686 7•2 26•1 -0•01 -0•04 -0•11 -0•9 
 Lung Cancer (Radon) 
-5 -309 -82 -203 -1•0 0•0 0•00 0•00 0•03 -3•4 
 Asthma (Mould) 
-523 0 -189 -261 0•5 3•0 0•00 -0•01 -0•02 -10•6 
 Depression (Cold) 
7,144 0 4,552 753 -13•6 -9•7 0•16 0•22 0•14 216•9 
NB: 
1
 Net Present Value over 2011-2030 (2010 prices); 
2
 Accumulated work-years over 2011-2030 without discounting; 
3 
Dependents are defined as members of the population outside working 
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age (mostly those surviving into retirement), 
4
IHD and stroke increase because of the increased air ;ghtness in some homes † GDP gains can be posi;ve even when per capita GDP gains are 
negative because of population growth 
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Discount Rate Sensitivity 
In addition to the two sensitivity analyses outlined above, we have also applied various 
discount rates in the model to illustrate the sensitivity of our results to the future value of the 
benefits.  The standard scenarios use a discount rate of 3.5%, we therefore applied values of 
3.0%, 4.0%, 4.5%, 5.0% to test sensitivity, a discount rate of 3% or above was selected for all 
scenarios to enable the real interest rate to remain positive under the model’s assumed 
inflation rate of 2.9%. 
 
The results of this sensitivity analysis are presented in Table E3.  This sensitivity analysis 
shows that, because of the 20 year duration of our modelling scenarios the overall 
macroeconomic gains vary considerably from £25.7bn for a discount rate of 3% to £19.5bn 
for a discount rate of 5% so the smaller discounting rate yields economic gains 24% larger 
than the largest discount rate.  Whilst it is important to highlight this sensitivity, we would 
also emphasise that this preliminary study was not intended to estimate precise magnitudes of 
economic gains from health co-benefits of greenhouse gas reductions, but rather to 
demonstrate that those economic gains were worthy of consideration as a means to partially 
compensate the cost of greenhouse gas reduction strategies.  This conclusion remains 
invariant to the changes in economic gains presented in this sensitivity analysis. 
 
Table E3 Discount Rate Sensitivity of  Aggregate Health Impact on GDP 
(NPV in 2010 prices) (£m) 
    Individual Scenarios   
 
Discount 
Rate 
 
Healthy 
Diet 
Active 
Travel 
Housing 
Insulation 
Combined 
Scenario 
3•0% ΔGDP (2011-2030) 4,982 20,233 476 
 
25,691 
3•5% (Standard) ΔGDP (2011-2030) 4,659 18,854 448 
 
23,960 
4•0% ΔGDP (2011-2030) 4,360 17,583 422 
 
22,365 
4•5% ΔGDP (2011-2030) 4,085 16,411 397 
 
20,893 
5•0% ΔGDP (2011-2030) 3,829 15,329 375 
 
19,534 
 
